Galderma, a skincare company in Switzerland, raised its full-year guidance after third-quarter sales surpassed expectations despite U.S. tariffs, causing shares to rise by 7%. Third-quarter net sales hit $1.29 billion, beating the expected $1.24 billion. The company expects a 17-17.7% increase in full-year net sales, up from the previous 12-14%.

Galderma reported strong growth in the U.S., with a 17.5% increase in third-quarter net sales compared to last year. The company plans to invest over $650 million in U.S. manufacturing by 2030. CEO Flemming Ornskov stated a shift in focus to the U.S. due to its strong growth.

Despite U.S. President Donald Trump’s 39% import duties on Switzerland, Galderma’s performance remains strong, leading to increased employment in the U.S., Europe, and Asia. The company expects continued growth in Europe. Galderma also raised its forecast core EBITDA margin to 23.1-23.6% at constant currency.

Galderma’s positive outlook and strong performance have led to an increase in employment across multiple regions. The company is closely monitoring the shifting U.S. tariff situation imposed by President Trump. The skincare company remains committed to growth and expansion in key markets like the U.S. and Europe.

Read more at Yahoo Finance: Galderma raises full-year outlook after sales beat, commits to US expansion